...
首页> 外文期刊>Bioorganic and medicinal chemistry >C17,20-lyase inhibitors I. Structure-based de novo design and SAR study of C17,20-lyase inhibitors.
【24h】

C17,20-lyase inhibitors I. Structure-based de novo design and SAR study of C17,20-lyase inhibitors.

机译:C17,20-裂解酶抑制剂I. C17,20-裂解酶抑制剂的基于结构的从头设计和SAR研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Novel nonsteroidal C(17,20)-lyase inhibitors were synthesized using de novo design based on its substrate, 17 alpha-hydroxypregnenolone, and several compounds exhibited potent C(17,20)-lyase inhibition. However, in vivo activities were found to be short-lasting, and in order to improve the duration of action, a series of benzothiophene derivatives were evaluated. As a result, compounds 9h, (S)-9i, and 9k with nanomolar enzyme inhibition (IC(50)=4-9 nM) and 9e (IC(50)=27 nM) were identified to have powerful in vivo efficacy with extended duration of action. The key structural determinants for the in vivo efficacy were demonstrated to be the 5-fluoro group on the benzothiophene ring and the 4-imidazolyl moiety. Superimposition of 9k and 17 alpha-hydroxypregnenolone demonstrated their structural similarity and enabled rationalization of the pharmacological results. In addition, selected compounds were also identified to be potent inhibitors of human enzyme with IC(50) values of 20-30 nM.
机译:新型非甾体类C(17,20)-裂合酶抑制剂是基于其底物,17α-羟基孕烯醇酮使用从头设计合成的,几种化合物均表现出有效的C(17,20)-裂合酶抑制作用。然而,发现体内活性是持久的,并且为了改善作用的持续时间,评估了一系列苯并噻吩衍生物。结果,鉴定出具有纳摩尔酶抑制(IC(50)= 4-9 nM)和9e(IC(50)= 27 nM)的化合物9h,(S)-9i和9k具有强大的体内功效,延长行动时间。证明体内功效的关键结构决定因素是苯并噻吩环上的5-氟基团和4-咪唑基部分。 9k和17α-羟基孕烯醇酮的叠加显示了它们的结构相似性,并使药理学结果合理化。此外,选定的化合物也被鉴定为人酶的有效抑制剂,IC(50)值为20-30 nM。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号